{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:50:05Z","timestamp":1791409805991,"version":"4.3.3"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.09.009","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:36:07Z","timestamp":1789400167000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2684-7311","authenticated-orcid":false,"given":"Hosana","family":"Candreva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6762-8930","authenticated-orcid":false,"given":"Mehak","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique Guimar\u00e3es Barbosa","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-5840","authenticated-orcid":false,"given":"Yujin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alabbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1452-039X","authenticated-orcid":false,"given":"Akihiro","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2026.09.009_bib0001","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/asheducation-2014.1.158","article-title":"Indolent lymphoma: follicular lymphoma and the microenvironment-insights from the microscope","volume":"2014","author":"Harris","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"21","key":"10.1016\/j.clml.2026.09.009_bib0002","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2017-11-764365","article-title":"Critical influences on the pathogenesis of follicular lymphoma","volume":"131","author":"K\u00fcppers","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.09.009_bib0003","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/imj.16454","article-title":"Diagnosis, management and follow-up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance","volume":"54","author":"Tobin","year":"2024","journal-title":"Intern Med J"},{"issue":"12","key":"10.1016\/j.clml.2026.09.009_bib0004","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ajh.26737","article-title":"Follicular lymphoma: 2023 update on diagnosis and management","volume":"97","author":"Jacobsen","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.09.009_bib0005","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.22.02327","article-title":"Randomized Phase III trial evaluating subcutaneous rituximab for the first-line treatment of low\u2013tumor burden follicular lymphoma: results of a LYSA study","volume":"41","author":"Cartron","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2026.09.009_bib0006","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1080\/10428194.2020.1779254","article-title":"Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort","volume":"61","author":"Madsen","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"10.1016\/j.clml.2026.09.009_bib0007","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood-2015-06-649905","article-title":"Cell of origin of transformed follicular lymphoma","volume":"126","author":"Kridel","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.09.009_bib0008","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1111\/bjh.70181","article-title":"Transformation and causes of death in follicular lymphoma: a Finnish nationwide population-based study","volume":"207","author":"Kalashnikov","year":"2025","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2026.09.009_bib0032","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaoncol.2026.0042","article-title":"Treatment of follicular lymphoma with CHOP and anti-CD20 therapy: 15-year follow-up of the SWOG S0016 trial","volume":"12","author":"Shadman","year":"2026","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.09.009_bib0009","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.3324\/haematol.2023.284538","article-title":"Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study","volume":"109","author":"Barraclough","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2026.09.009_bib0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"10438","key":"10.1016\/j.clml.2026.09.009_bib0010","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","article-title":"B-cell non-Hodgkin lymphomas","volume":"403","author":"Silkenstedt","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.09.009_bib0011","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ajh.25696","article-title":"Follicular lymphoma: 2020 update on diagnosis and management","volume":"95","author":"Freedman","year":"2020","journal-title":"Am J Hematol"},{"issue":"9383","key":"10.1016\/j.clml.2026.09.009_bib0031","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"British National Lymphoma Investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clml.2026.09.009_bib0012","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1016\/S1470-2045(13)70450-9","article-title":"Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines","volume":"14","author":"Tan","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.09.009_sbref0013","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2023"},{"key":"10.1016\/j.clml.2026.09.009_bib0014","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.clml.2026.09.009_bib0015","article-title":"RoB 2: a revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2026.09.009_bib0016","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.clml.2026.09.009_bib0017","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/S2352-3026(25)00034-1","article-title":"Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial","volume":"12","author":"Northend","year":"2025","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2026.09.009_bib0019","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2024-199868","article-title":"Randomized Phase III study of watchful waiting vs. Rituximab As first-line treatment in patients with advanced stage low tumor burden follicular lymphoma: jCOG1411\/Flora study","volume":"144","author":"Fukuhara","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2026.09.009_bib0018","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2020-136457","article-title":"Rituximab monotherapy compared to observation in patients with newly diagnosed asymptomatic advanced stage follicular lymphoma: a retrospective population-based analysis","volume":"136","author":"Perry","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.09.009_bib0021","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1470-2045(04)01490-1","article-title":"Non-Hodgkin lymphoma: an update","volume":"5","author":"Hennessy","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.09.009_bib0022","unstructured":"Benefit suggested for early treatment of advanced-stage very low-tumor-burden follicular lymphoma. ASCO Post. Available at: https:\/\/ascopost.com\/issues\/march-25-2025\/benefit-suggested-for-early-treatment-of-advanced-stage-very-low-tumor-burden-follicular-lymphoma\/. Accessed: May 17, 2026."},{"issue":"2","key":"10.1016\/j.clml.2026.09.009_bib0023","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/annonc\/mdx768","article-title":"Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas","volume":"29","author":"Karmali","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.09.009_bib0024","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/bjh.19918","article-title":"Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful waiting","volume":"206","author":"Marzolini","year":"2025","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2026.09.009_bib0025","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","article-title":"Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab","volume":"130","author":"Athni","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.clml.2026.09.009_bib0026","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1016\/S2352-3026(25)00105-X","article-title":"Rituximab versus active surveillance in patients with follicular lymphoma","volume":"12","author":"Kimby","year":"2025","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.clml.2026.09.009_bib0027","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.09.009_bib0028","article-title":"SWOG 2308: randomized Phase III study of Mosunetuzumab versus Rituximab for low-tumor burden follicular lymphoma","volume":"2","author":"Ghosh","year":"2025","journal-title":"JCO Oncol Adv"},{"issue":"11","key":"10.1016\/j.clml.2026.09.009_bib0029","doi-asserted-by":"crossref","first-page":"e1236","DOI":"10.1634\/theoncologist.2019-0138","article-title":"Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs","volume":"24","author":"Matasar","year":"2019","journal-title":"Oncologist"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026032957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026032957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:00:22Z","timestamp":1791406822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026032957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"alternative-id":["S2152265026032957"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}